Fullife Raises Rs 300 Cr, IPO Plans a Few Years Away
A fast-growing D2C nutrition brand is doubling down on expansion. Fullife Healthcare, the parent of Fast&Up and Chicnutrix, has raised Rs 300 crore in a Series D funding round led by Elev8 Venture Partners. This marks the investor’s entry into the D2C space. The company plans to use the funds... The post Fullife Raises Rs 300 Cr, IPO Plans a Few Years Away appeared first on Equitypandit.
A fast-growing D2C nutrition brand is doubling down on expansion. Fullife Healthcare, the parent of Fast&Up and Chicnutrix, has raised Rs 300 crore in a Series D funding round led by Elev8 Venture Partners. This marks the investor’s entry into the D2C space.
The company plans to use the funds to scale manufacturing, invest in product innovation and R&D, and expand domestic distribution. Additionally, it will strengthen its presence in international markets such as the UK and the UAE.
Despite strong growth, an IPO is not an immediate priority. The company indicated that public listing plans depend on both business readiness and favourable market conditions. Therefore, timelines are likely a few years away.
Fullife has reported strong momentum, with year-over-year growth of around 100% over the past two years. It is approaching Rs 600 crore in annual recurring revenue (ARR) for FY26.
The company is also focusing on enhancing in-house manufacturing and ensuring the clinical validation of its products. It seeks to build credibility in a competitive yet fast-growing segment.
Investors remain optimistic about the broader new-age consumer brand space, which is still underpenetrated in many niches. This space is expected to see significant growth over the next few years.
Ready to invest like a pro? Tradz by EquityPandit equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz app and gain access to daily stock lists and insightful market analysis and much more!
The post Fullife Raises Rs 300 Cr, IPO Plans a Few Years Away appeared first on Equitypandit.
What's Your Reaction?
